Johnson & Johnson JNJ

$285.75 +2.23 (0.79%)

Valuation

Market cap
682,520,576,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
26.33
P/E (forward)
25.22
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
6,291,200
Avg volume
7,238,710
Day's range
$281.68 – $288.11
Shares out
2,407,310,000
Stochastic %K
90%
Beta
0.22
Analysts
Moderate Buy
Price target
$281.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

JLEKnowTheFuture Nov 14, 12:56 AM
$JNJ glad I took a full position in this back in January, 2025. Up 99.72%.
0 replies
frb1985 Nov 13, 9:09 PM
$JNJ is that another all time high. I miss Suite and Outcomes. LOL 😆
0 replies
HydrogenH2 Nov 13, 8:36 PM 0 replies
thinkandpick Nov 13, 6:36 PM
$INMD $JNJ $BSX $MDT $SYK Medical device stocks. Dirt-cheap InMode (INMD) is a key beneficiary from the fact that male aesthetic treatments and products will SURGE in the foreseeable future: https://mensfitness.co.uk/health/the-male-beauty-boom-why-men-are-finally-embracing-everything-from-laser-facial-treatments-to-botox/
0 replies
HydrogenH2 Nov 13, 5:20 PM
$JNJ When Cramer says "Buy" start "Selling" lol 😜😝
0 replies
TraderDaKing Nov 13, 5:10 PM
$ELTP $PFE $JNJ $MRNA Make Room for ELTP.... We are in. this is Huge News. If you did not hear the call, you must replay and listen. We are going to the Moon. This is the Cheapest the stock will ever be. Thank You.
0 replies
TraderDaKing Nov 13, 4:50 PM
$ELTP $GME $JNJ $PLCE Elite Pharmaceuticals, Inc. (Elite Pharmaceuticals, Inc.) will be trade on the NASDAQ exchange next year, per conference call... Yes there it is........
0 replies
SellasgpsCurativeBAT11 Nov 13, 4:38 PM
$ABBV $BMY $JNJ $PFE $SLS Data is a Overwhelming success is a forgone conclusion for me. As a Biostatistician Sellas GPS has blown past all my Analysis. I am here for the Big Pharmaceutical BO. Sellas has structured itself so lean for an immediate BO after Top Line Data. 👇✌️🙏❤️‍🩹
1 replies